--- title: "U.S. stock night market volatility: FDA restarts review + rating upgrade, Capricor surges 58%" type: "News" locale: "en" url: "https://longbridge.com/en/news/296043682.md" description: "Capricor Therap rose 3.16% in after-hours trading; Skye Bioscience rose 36.43% in after-hours trading, with a transaction volume of USD 619,500; BeiGene rose 1.02% in after-hours trading, with a transaction volume of USD 203,800; MDxHealth SA fell 12.70% in after-hours trading, with a transaction volume of USD 129,200" datetime: "2026-08-17T01:46:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296043682.md) - [en](https://longbridge.com/en/news/296043682.md) - [zh-HK](https://longbridge.com/zh-HK/news/296043682.md) --- # U.S. stock night market volatility: FDA restarts review + rating upgrade, Capricor surges 58% **U.S. Stock Night Market Movements** Capricor Therap rose 3.16% in the night market. Based on recent key news: 1. On August 15, the U.S. FDA agreed to review the latest data for Capricor Therap's Duchenne muscular dystrophy drug Deramiocel, driving the stock price up by 57.36%. Cantor Fitzgerald upgraded the stock rating to "overweight," significantly raising the target price from $3.50 to $28. Source: Zhitong Finance 2. On August 14, Capricor Therap announced plans to submit supplementary trial data showing the benefits of its drug on upper limb muscle function. The FDA expressed willingness to review the amendment and extend the PDUFA action date. This news propelled the stock price up by 67.7%. Source: Reuters 3. On August 14, Capricor Therap's trading volume exceeded 42 million shares, approximately 8.2 times the 30-day average trading volume, indicating market optimism regarding its drug approval. Source: CNBC The biotechnology industry has recently been significantly affected by FDA approval dynamics. **Stocks with High Trading Volume in the Industry** Skye Bioscience rose 36.43% in the night market. Based on recent key news: 1. On August 14, Skye Bioscience announced the termination of all nimacimab development and initiated a cost-cutting plan. Due to competitive pressure and poor trial results, the company decided to terminate the project and implement cost reductions. This news boosted investor confidence, driving the stock price up. 2. On August 14, Skye Bioscience reached an acquisition deal with Redx Pharma and plans to conduct a reverse stock split to meet Nasdaq requirements. This acquisition includes significant financing aimed at enhancing the company's financial condition and market competitiveness, further driving the stock price up. 3. On August 14, Skye Bioscience merged with Redx Pharma to form a company focused on fibrosis treatment and secured $125 million in financing. The merged company will focus on fibrosis treatment for Crohn's disease, with phase II data expected to be released in 2029. This news further strengthened market confidence in the company's future development, driving the stock price up. The fibrosis treatment field has broad prospects, attracting high investor attention. BeiGene rose 1.02% in the night market. Based on recent key news: 1. On August 11, JP Morgan increased its holdings in BeiGene by 4.11972 million shares, raising its ownership stake to 9.05%, indicating institutional confidence in the company and driving the stock price up. Source: Zhitong Finance 2. Since August, BeiGene has received research inquiries from over 200 institutions, indicating increased market attention on the innovative drug sector, further supporting the stock price increase. Source: 21st Century Business Herald 3. On August 14, some products received breakthrough therapy designation from the CDE, leading to advanced R&D progress and enhancing market confidence in the company's future development. Source: Daily Economic News, increased attention on the pharmaceutical sector, active institutional research. MDxHealth SA fell 12.70% in after-hours trading. Based on recent key news: 1. On August 14, MDxHealth SA reported a 16% year-on-year increase in second-quarter revenue, reaching $27.2 million, but operational losses widened due to the integration of ExoDx. Nevertheless, the company maintained its revenue guidance for 2026 and expects adjusted EBITDA to return to positive territory. This news failed to alleviate market concerns about the widening losses, leading to a decline in stock price. 2. On August 15, the company raised $20 million through a registered direct financing, eliminating $10.4 million in contingent liabilities and strengthening its balance sheet and cash position. Despite the improvement in financial condition, market concerns about future profitability remain, affecting stock performance. 3. On August 15, Lake Street maintained a buy rating on MDxHealth, indicating analysts' confidence in the company's long-term growth potential. However, short-term market concerns about profitability continue to dominate stock price movements. The diagnostic industry is experiencing strong growth, while macroeconomic uncertainty is increasing ### Related Stocks - [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md) - [SKYE.US](https://longbridge.com/en/quote/SKYE.US.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [MDXH.US](https://longbridge.com/en/quote/MDXH.US.md) ## Related News & Research - [Capricor Therapeutics (CAPR) Could Be 89% Undervalued Following Deramiocel And Loss Concerns](https://longbridge.com/en/news/296098763.md) - [06:15 ETCAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman](https://longbridge.com/en/news/296212321.md) - [Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval](https://longbridge.com/en/news/295942560.md) - [Are Capricor Therapeutics’ (CAPR) Rising Losses Reframing the Risk-Reward Balance of Its Pipeline Strategy?](https://longbridge.com/en/news/295994950.md) - [CAPR Deadline Alert: SueWallSt Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Securities Class Action Deadline on September 28, 2026](https://longbridge.com/en/news/295825975.md)